Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 5/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938130 | 0.83 | RAF1 (0.74) | RAF1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1506322 | 0.81 | RAF1 (0.78) | RAF1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL939468 | 0.80 | RAF1 (0.64) | RAF1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL938856 | 0.79 | RAF1 (0.56) | RAF1PDGFRBKDRBRAF | |
| SCHEMBL938807 | 0.78 | FLT3 (0.58) | RAF1KDRBRAF | |
| SCHEMBL937084 | 0.77 | MAPK14 (0.57) | RAF1BRAF | |
| SCHEMBL548328 | 0.74 | RAF1 (0.79) | RAF1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4340280 | 0.73 | RAF1 (0.74) | RAF1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22125514 | 0.72 | SMARCA2 (0.66) | RAF1KDR | |
| SCHEMBL4342542 | 0.72 | HDAC3 (0.73) | RAF1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242147-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2012-08-14 | — | — | US | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2289515-A2 | Combinations comprising a diaryl urea and an interferon | Bayer HealthCare LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | DUMAS JACQUES | 2011-01-20 | — | — | US | disclosed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | BAYER PHARMACEUTICALS CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | BAYER HEALTHCARE LLC | 2008-09-18 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885HDAC3 2064/4885HDAC4 1888/4885 |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | RAF1 51/4885HDAC3 2720/4885HDAC4 2776/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | RAF1 867/4885HDAC3 2064/4885HDAC4 1888/4885 |
| US-20110015195-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885HDAC3 2064/4885HDAC4 1888/4885 |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | FLT1, FLT4, KDR | RAF1 867/4885HDAC3 2064/4885HDAC4 1888/4885 |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | NR4A1, NAP1L4, NR4A3 | RAF1 4118/4885HDAC3 1042/4885HDAC4 170/4885 |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | FLT4, FLT1, KDR | RAF1 817/4885HDAC3 2417/4885HDAC4 1808/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885HDAC3 2064/4885HDAC4 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.